Tumour-derived apolipoprotein E drives temozolomide chemoresistance by reprogramming lipid metabolism and activating the homologous recombination repair pathway in pancreatic neuroendocrine tumours

#4428

Introduction: Temozolomide (TMZ) is a first-class clinical drug for patients with pancreatic neuroendocrine tumours (pNETs). However, the therapeutic effects of TMZ are limited because of the chemoresistance of pNET cells.

Aim(s): Strategies to overcome chemoresistance and improve patient outcomes are of clinical importance.

Materials and methods: ELISA was used to investigate the expression levels of APOE in the peripheral blood of patients and in the cell culture supernatant. The transcriptome, proteome, and chromatin immunoprecipitation analyses were used.

Conference:

Presenting Author: Ji S

Authors: Lou X, Ji S, Xu X, Chen J, Yu X,

Keywords: Temozolomide, pancreatic neuroendocrine tumour, chemoresistance,